1. Academic Validation
  2. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy

  • Nat Med. 1998 Jul;4(7):822-6. doi: 10.1038/nm0798-822.
C Soto 1 E M Sigurdsson L Morelli R A Kumar E M Castaño B Frangione
Affiliations

Affiliation

  • 1 Department of Pathology, New York University Medical Center, New York 10016, USA. Claudio.Soto@mcfpo.med.nyu.edu
Abstract

Inhibition of cerebral amyloid beta-protein deposition seems to be an important target for Alzheimer's disease therapy. Amyloidogenesis could be inhibited by short synthetic Peptides designed as beta-sheet breakers. Here we demonstrate a 5-residue peptide that inhibits amyloid beta-protein fibrillogenesis, disassembles preformed fibrils in vitro and prevents neuronal death induced by fibrils in Cell Culture. In addition, the beta-sheet breaker peptide significantly reduces amyloid beta-protein deposition in vivo and completely blocks the formation of amyloid fibrils in a rat brain model of amyloidosis. These findings may provide the basis for a new therapeutic approach to prevent amyloidosis in Alzheimer's disease.

Figures
Products